Our science

Target Discovery & Validation

iTeos uses a platform of in vitro and ex vivo screening assays to reproduce immunosuppression induced by different components of the tumor microenvironment.

iTeos has developped an innovative phenotypic screening platform that is applied to the identification of rational combinations for our current programs, and to the discovery of novel targets for immuno-oncology. This effort is complemented by collaborations with top tier universities to profile cancer samples of patients treated with immunotherapies.